Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Amylyx Pharmaceuticals Announces Successful Phase 3 LUCIDITY Trial Results for Avexitide in Post-Bariatric Hypoglycemia
42+ min ago (109+ words) Borr Drilling (NYSE:BORR): Is the Market Missing Something? Genpact (NYSE:G): Can AI Momentum Keep Building? Amer Sports (NYSE:AS) Results Put Growth Back In Focus Molina Healthcare (NYSE:MOH): What Could Shift Next? On August 18, 2026, Amylyx Pharmaceuticals, Inc. submitted…...
Amylyx's avexitide cuts hypoglycemic events by 55% in Phase III post-bariatric trial
2+ hour, 33+ min ago (656+ words) AllSci Avexitide, a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, met the primary endpoint of the Phase III LUCIDITY trial in post-bariatric hypoglycemia (PBH), delivering a 55% reduction in composite Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003), according to topline results…...
Harvard-Trained Gastroenterologist Shares 10 Foods That Can Help Fight Inflammation
1+ hour, 8+ min ago (292+ words) Inflammation is a natural response in the body, but when it continues for a long time, it affects overall health. What we eat can also play a role, as certain food items can support the body while others may make…...
Amylyx drug cuts low blood sugar episodes in bariatric surgery patients in key trial
59+ min ago (270+ words) Aug 18 (Reuters) – Amylyx Pharmaceuticals’ experimental drug met its main goal in a late-stage trial for post-bariatric hypoglycemia, a condition marked by dangerously low blood sugar levels following weight-loss surgery, sending its shares up over 30% in premarket trading on Tuesday. In…...
Amylyx Announces Phase 3 LUCIDITY: Avexitide Cuts Level 2/3 Hypoglycemic Events 55% vs Placebo
3+ hour, 37+ min ago (158+ words) TradingView Amylyx Announces Phase 3 LUCIDITY: Avexitide Cuts Level 2/3 Hypoglycemic Events 55% vs Placebo Amylyx reported positive topline Phase 3 LUCIDITY results showing avexitide reduced composite Level 2 and Level 3 hypoglycemic events by 55% versus placebo (p=0.000003). - LUCIDITY (78 participants) met FDA‑agreed primary endpoint: 55% reduction…...
Hearing loss and dementia link can drive implant growth
7+ hour, 43+ min ago (401+ words) An Australian company that pioneered hearing implants sees its future growth in the ongoing "medicalisation" of adult hearing loss, after suffering a fall in earnings on softer markets in the Middle East and China. But chief executive Dig Howitt says…...
Lactose intolerant? Here’s what you need to know about consuming dairy
1+ hour, 16+ min ago (204+ words) Being lactose intolerant does not always mean that you have to skip dairy products entirely. However, you must be wise and careful in your decisions to incorporate dairy in your diet in a way that it doesn't worsen your health....
Erection Drug for Longevity? Soda and Stomach Cancer; Luigi Mangione Trial Postponed
1+ hour, 14+ min ago (290+ words) — Health news and commentary gathered by MedPage Today staff Note that some links may require registration or subscription. The erectile dysfunction drug tadalafil (Cialis) is being hyped in wellness circles for unproved longevity benefits. (NPR) The New York Times took…...
Diabetes prevention starts as early as conception, experts say
3+ hour, 12+ min ago (319+ words) Preventing type 2 diabetes could require action much earlier in life, according to experts calling for a new approach to protecting metabolic health. Around 90–95% of people living with diabetes have type 2 diabetes, which develops through a complex combination of genetic, biological,…...
AI-led Diabetes Prevention Programme Proves Unsatisfying for Patients
10+ hour, 50+ min ago (555+ words) AN AI-DRIVEN diabetes prevention programme which has faster, more consistent patient engagement than a human-coach led programme was unsatisfying for patients, according to new research. A new randomised trial found that found that AI-powered lifestyle intervention for patients with prediabetes…...